Accelerating discovery and commercialization with AI
Discovery and commercialization are gated by documents, data, and timelines. We build AI that compresses them — matching patients to trials, accelerating regulatory work, and giving R&D and commercial leaders a live view of portfolio risk and return.
Why AI mattersin Life Sciences.
In life sciences, breakthroughs are gated by documents, data, and time. AI matters when it compresses those cycles without compromising scientific or regulatory rigor.
Our point of view is value first, measured in dollars and timelines. We pursue quantifiable ROI over impressive demos, amplify your scientists and reviewers rather than replace them, and build inside your validated, governed environment.
- 01Time is the costEvery month of delay is value lost.
- 02Documents gate everythingTrials and submissions drown in paperwork AI can read.
- 03Rigor can't slipSpeed only counts inside a validated process.
- 04Data is the assetDecades of research, finally searchable.
The AI opportunityin Life Sciences.
faster regulatory document prep
highest-value AI use cases mapped per function
target ROI within 90 days
Photo: Pexels
Purpose-built applicationsfor Life Sciences.
Intelligent Clinical Trial Matching
An AI agent scans patient records, trial eligibility criteria, and site capacity in real time — automatically surfacing the best candidates and reducing enrollment timelines by months.
CRFT builds the matching engine, integrations, and investigator portal.
Regulatory Submission Accelerator
Compress months of regulatory document preparation into weeks — AI drafts, cross-references, and validates submissions against FDA and EMA requirements automatically.
CRFT engineers the document intelligence pipeline from ingestion to submission-ready output.
R&D Portfolio Intelligence
A live dashboard tracks the ROI trajectory of every compound in your pipeline — flagging risk signals, budget overruns, and competitive shifts before quarterly reviews.
KNTRL provides real-time portfolio visibility and optimization signals.
AI Opportunity Mapping for Pharma
Consider a structured assessment that identifies the 5 highest-value AI use cases across your commercial, medical affairs, and supply chain functions — with projected returns.
SPRK delivers the diagnostic and ROI-backed activation roadmap.
The Accountability Gap: What Private Equity Gets Wrong About Measuring AI
A four-lens framework for capturing the full spectrum of AI value — and risk — across every dimension that matters to PE sponsors, operators, and boards.
Pablo Cruz Pou & Fritz Desir · May 30, 2026 · 17 min read
The Agentic Enterprise: A Field Report
What we learned putting AI agents into real operations — where they earned their keep, and where they quietly fell over.
Fritz Desir · May 28, 2026 · 3 min read
Buy, Build, or Activate: A Framework for Enterprise AI
Most AI decisions get framed as buy-vs-build. That's the wrong axis — and it's why so much AI spend underperforms.
Fritz Desir · May 26, 2026 · 3 min readLife Sciences,answered.
We design for your validated environment from day one — defining where AI drafts and where qualified reviewers approve, with full traceability for audit and inspection readiness.